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PreviewsIRF-3 Releases Its Inhibitions
Interferon regulatory factor (IRF) 3 plays a critical role
in triggering the activation of interferon antiviral
genes. The structure of IRF-3 in association with the
CBP/p300 coactivator by Qin et al. (2005) in this issue
of Structure illuminates the mechanism of IRF activa-
tion and the structural flexibilities inherent in CBP/
p300.
Rapid induction of type I interferon (IFN) expression is a
central event in the establishment of the innate immune
response against viral infection and requires the activa-
tion of multiple transcriptional proteins following engage-
ment and signaling through Toll-like receptor-dependent
and -independent pathways (Akira and Takeda, 2004;
Yoneyama et al., 2004). The transcription factor IRF-3
contributes to a first line of defense against viral infec-
tion by inducing the production of interferons and cyto-
kines that in turn stimulate the development of antiviral
activity and immune response modulation. The ab-
sence of IRF-3 or the closely related IRF-7 in murine
knockout models results in dramatically reduced IFN
production and increased viral pathogenesis, thus sup-
porting a pivotal role for IRF3/IRF7 in the development
of the host antiviral response (Sato et al., 2000).
IRF-3 is a constitutively expressed phosphoprotein
with an amino-terminal tryptophan repeat-containing
DNA binding domain and a carboxyl-terminal IRF asso-
ciation domain (IAD) and transactivation domain. The
transcriptional activity of IRF-3 is controlled by carboxyl-
terminal phosphorylation events on serines 385 and
386 (Yoneyama et al., 1998) and the serine/threonine
cluster between aa 396 and 405 (Lin et al., 1999), medi-
ated by the IKK-related kinases TBK-1 and IKK (Fitz-
gerald et al., 2003; Sharma et al., 2003) (Figure 1).
Based on available biochemical data, a model for
IRF-3 activation proposed that phosphorylation within
the serine/threonine cluster induced a conformational
change in IRF-3 that allowed homo- and hetero-oligo-
merization, nuclear localization, and association with
the histone acetyltransferase coactivator CBP/p300
(Lin et al., 1999). Inactive IRF-3 constitutively shuttles
in and out of the nucleus, whereas phosphorylation-
dependent association with CBP/p300 retains IRF-3 in
the nucleus and induces transcription of IFN α/β genes,
the chemokine RANTES, and the IFN-stimulated genes.
In 2003, two studies revealed the X-ray crystallo-
graphic structure of the carboxyl terminal domain of
IRF-3 (Figure 1) (Qin et al., 2003; Takahasi et al., 2003).
Qin and colleagues interpreted the structure in light of
an autoinhibitory mechanism in which amino- and car-
boxyl-terminal α-helical structures flanking a β sand-
wich IAD core interacted to form a condensed hy-
drophobic structure. The interaction buried several key
residues involved in dimerization of the active protein
and suggested that virus-induced phosphorylation un-
folded the autoinhibitory structures by introducing chargerepulsions that opened the hydrophobic surface for
functional interactions. Qin and colleagues maintained
that sequential phosphorylation events at the carboxyl
terminus were required for relief of autoinhibition (Qin
et al., 2003). A parallel structural study opposed the
existence of an autoinhibitory mechanism and asserted
that phosphorylation of the carboxyl terminus directly
precipitated IRF-3 dimerization, and also suggested
that CBP/p300 interacted with a large acidic surface on
IRF-3 formed as a result of subunit dimerization (Taka-
hasi et al., 2003).
In the current issue of Structure, Qin et al. (2005) now
describe the crystal structure of a complex between
the IRF-3 binding domain (IBiD) of the histone acetyl-
transferase CBP/p300 with the IRF association domain
(IAD) of IRF-3 at 2.4 Å resolution (Figure 1) (Qin et al.,
2005). The structure reveals that the IBiD binds to a
hydrophobic surface on IAD, which in latent IRF-3 is
buried by the autoinhibitory elements. The H3 and the
H4 helices are masked by intramolecular interactions in
the crystal structure of latent IRF-3 (Figure 1) (Qin et al.,
2003). The structure revealed that the IAD of IRF-3 and
IBiD of CBP form a 1:1 complex through their respective
α-helical regions. The IRF-3/IBiD complex illustrates that
the IBiD covers the same surface as the autoinhibitory
elements in latent IRF-3, indicating that the autoinhibi-
tory conformation of latent IRF-3 and the interaction of
IRF-3 with IBiD are mutually exclusive (Qin et al., 2005).
Consequently, these autoinhibitory elements must be
displaced during activation to allow CBP interactions,
consistent with virus-induced phosphorylation and un-
folding of the C-terminal segment.
Formation of a nucleoprotein complex between CBP/
p300 and multiple, structurally diverse transcription
factors, together with acetylation of histones and tran-
scription factors, leads to chromatin relaxation and
transcription factor activation. The IBiD of CBP/p300
maps to a 46 residue segment in the C-terminal gluta-
mine rich-region of the protein and interacts with sev-
eral other comodulators such as Ets2, p53, and the
nuclear receptor coactivator protein ACTR (Lin et al.,
2001). Strikingly, the interacting CBP segment can exist
in different conformations depending on the associated
transcription cofactor. When the NMR structures of un-
complexed IBiD and IBiD complexed with TIF2 were
determined, both structures revealed a helical frame-
work for IBiD; however, the conformations of IBiD in the
two structures differed, with IBiD undergoing a confor-
mational transition upon interaction with comodulator
that increased the helical nature of IBid (Lin et al.,
2001). The current results with IRF-3 further support the
existence of an inherent flexibility in CBP/p300 IBiD
conformation that permits association with diverse tran-
scriptional regulators. The results suggest a regulatory
mechanism in which IBiD can stabilize CBP/p300 in
one of its multiple conformations to influence transcrip-
tional outcome.
The crystal structure of the IRF-3/IBiD complex clearly
supports the autoinhibitory mechanism for maintaining
IRF-3 in a latent state in noninfected cells. However, be-
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1236Figure 1. Ribbon Diagrams Illustrate the Interactions between the
IAD of IRF-3 and the IBiD Region of CBP
Left: Intramolecular interactions between the IAD of IRF-3 (in green)
and the flanking autoinhibitory structures (in red). Phosphorylation
sites are in yellow. Right: Intermolecular interactions between the
IAD of IRF-3 (in green) and the IBiD region of CBP (in blue). The
figure was graciously provided by Kai Lin.
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association are only partially conserved in other IRF
family members, alternate structural motifs and distinct
conformations of CBP/p300 may be a necessity to
achieve these functional interactions.
While this study provides interesting new perspec-
tives on IRF-3 association with CBP/p300, many impor-
tant questions remain that will likely have to await
structural verification. For example, the structure of full-
length IRF-3 with both the DNA binding domain and the
IAD has yet to be resolved. Models derived from do-
main structures may not fully describe the functional
interactions of the full-length proteins. In particular, it
will be essential to correlate structural models with
functional phosphorylation: Is it possible to identify ex-
perimentally intermediate IRF-3 structures representing
different states of phosphorylation and/or activation?
How does the structure of the functionally related IRF-7
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aorrelate with the three-dimensional information avail-
ble for IRF-3? The answers to these and other impor-
ant questions will provide insights to the mechanisms
f transcriptional regulation in general and to the trig-
ering of antiviral immunity in particular.
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